Sarcoma  >>  tidutamab (XmAb18087)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tidutamab (XmAb18087) / Xencor
DUET-1, NCT03411915: A Study of XmAb®18087 in Subjects With NET and GIST

Completed
1
62
US
XmAb18087
Xencor, Inc., ICON plc
Neuroendocrine Tumor, Gastrointestinal Neoplasm
10/21
10/21

Download Options